Overview

Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia

Status:
Recruiting

Trial end date:
2022-06-30

Target enrollment:

Participant gender:

Summary

This phase II trial studies the side effects and how well larotrectinib works in treating patients with previously untreated TRK fusion solid tumors and TRK fusion acute leukemia that has come back. Larotrectinib may stop the growth of cancer cells with TRK fusions by blocking the TRK enzymes needed for cell growth.

Phase:

Phase 2

Details

Lead Sponsor:

Children's Oncology Group

Collaborator:

National Cancer Institute (NCI)